Published in Bioorg Med Chem Lett on February 07, 2006
6-Meth-oxy-4-methyl-2H-chromen-2-one. Acta Crystallogr Sect E Struct Rep Online (2010) 0.95
The discovery of setileuton, a potent and selective 5-lipoxygenase inhibitor. ACS Med Chem Lett (2010) 0.80
Microwave-assisted synthesis and antioxidant properties of hydrazinyl thiazolyl coumarin derivatives. Chem Cent J (2012) 0.78
MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther (2008) 1.91
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes (2005) 1.70
Carrageenan-induced paw edema in rat elicits a predominant prostaglandin E2 (PGE2) response in the central nervous system associated with the induction of microsomal PGE2 synthase-1. J Biol Chem (2004) 1.67
Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest (2002) 1.62
Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation (2002) 1.62
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett (2008) 1.60
A slow life in hell or a fast life in heaven: demographic analyses of contrasting roe deer populations. J Anim Ecol (2009) 1.40
Deletion of microsomal prostaglandin E2 (PGE2) synthase-1 reduces inducible and basal PGE2 production and alters the gastric prostanoid profile. J Biol Chem (2004) 1.29
Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg Med Chem Lett (2006) 1.29
Statistical and graphical methods for quality control determination of high-throughput screening data. J Biomol Screen (2003) 1.27
MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther (2008) 1.23
A new class of small molecule RNA polymerase inhibitors with activity against rifampicin-resistant Staphylococcus aureus. Bioorg Med Chem (2006) 1.23
Maternal and individual effects in selection of bed sites and their consequences for fawn survival at different spatial scales. Oecologia (2008) 1.20
Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. Bioorg Med Chem Lett (2005) 1.15
Patterns of body mass senescence and selective disappearance differ among three species of free-living ungulates. Ecology (2011) 1.14
Antler size provides an honest signal of male phenotypic quality in roe deer. Am Nat (2007) 1.09
Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem (2008) 1.08
Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med (2005) 1.07
Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation. Curr Med Chem (2003) 1.06
A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds. Bioorg Med Chem Lett (2006) 1.06
Discovery, biosynthesis, and structure elucidation of metabolites of a doping agent and a direct analogue, tetrahydrogestrinone and gestrinone, using human hepatocytes. Anal Chem (2005) 1.06
Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors. Bioorg Med Chem Lett (2007) 1.05
Catalytic inactivation of protein tyrosine phosphatase CD45 and protein tyrosine phosphatase 1B by polyaromatic quinones. Biochemistry (2004) 1.05
Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem (2005) 1.04
Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis. J Pharmacol Exp Ther (2006) 1.02
Variations in adult body mass in roe deer: the effects of population density at birth and of habitat quality. Proc Biol Sci (2002) 1.01
The C3a receptor antagonist SB 290157 has agonist activity. Immunol Lett (2005) 1.01
Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors. J Med Chem (2003) 1.01
Quantitation of the lysosomotropic character of cationic amphiphilic drugs using the fluorescent basic amine Red DND-99. Anal Biochem (2004) 1.01
Fitness consequences of environmental conditions at different life stages in a long-lived vertebrate. Proc Biol Sci (2014) 0.99
Kinetic characterization and identification of a novel inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 using a time-resolved fluorescence resonance energy transfer-based assay technology. Anal Biochem (2008) 0.99
Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors. J Med Chem (2002) 0.99
No difference between the sexes in fine-scale spatial genetic structure of roe deer. PLoS One (2010) 0.99
New 'chemical probes' to examine the role of the hFPRL1 (or ALXR) receptor in inflammation. Bioorg Med Chem Lett (2007) 0.99
Discovery of a potent and selective agonist of the prostaglandin EP4 receptor. Bioorg Med Chem Lett (2003) 0.97
Evaluation of VCH-759 monotherapy in hepatitis C infection. J Hepatol (2009) 0.97
Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. Biochemistry (2002) 0.97
Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. J Med Chem (2011) 0.97
Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors. J Pharmacol Exp Ther (2005) 0.96
Heterozygosity-fitness correlations revealed by neutral and candidate gene markers in roe deer from a long-term study. Evolution (2008) 0.96
Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem (2007) 0.95
Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438). Bioorg Med Chem Lett (2009) 0.95
Effect of cathepsin k inhibitor basicity on in vivo off-target activities. Mol Pharmacol (2007) 0.95
Identification of a potent and selective non-basic cathepsin K inhibitor. Bioorg Med Chem Lett (2006) 0.94
HIP1-ALK, a novel ALK fusion variant that responds to crizotinib. J Thorac Oncol (2014) 0.93
In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother (2013) 0.93
Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors. Bioorg Med Chem Lett (2009) 0.93
Down-regulation of microsomal prostaglandin E2 synthase-1 in adipose tissue by high-fat feeding. Obesity (Silver Spring) (2007) 0.93
Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing. J Biol Chem (2007) 0.92
Inhibition of inducible prostaglandin E(2) synthase by 15-deoxy-Delta(12,14)-prostaglandin J(2) and polyunsaturated fatty acids. Biochem Pharmacol (2002) 0.92
Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic, [3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone], in multiple preclinical species. Eur J Pharmacol (2007) 0.92
Bigger teeth for longer life? Longevity and molar height in two roe deer populations. Biol Lett (2007) 0.92
An activity-based probe for the determination of cysteine cathepsin protease activities in whole cells. Anal Biochem (2004) 0.91
Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K. J Med Chem (2005) 0.91
Adenovirus IL-13-induced airway disease in mice: a corticosteroid-resistant model of severe asthma. Am J Respir Cell Mol Biol (2008) 0.90
Discovery of novel hydroxy-thiazoles as HIF-alpha prolyl hydroxylase inhibitors: SAR, synthesis, and modeling evaluation. Bioorg Med Chem Lett (2008) 0.90
Population density and phenotypic attributes influence the level of nematode parasitism in roe deer. Oecologia (2011) 0.88
Thiazole analog as stearoyl-CoA desaturase 1 inhibitor. Bioorg Med Chem Lett (2009) 0.88
Purification and characterization of recombinant microsomal prostaglandin E synthase-1. Protein Expr Purif (2002) 0.87
(2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors. Bioorg Med Chem Lett (2004) 0.87
In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. Am J Vet Res (2004) 0.87
Detection of covalent adducts to cytochrome P450 3A4 using liquid chromatography mass spectrometry. Chem Res Toxicol (2004) 0.87
Development of a homogeneous immunoassay for the detection of angiotensin I in plasma using AlphaLISA acceptor beads technology. Anal Biochem (2009) 0.87
A novel class of nonpeptidic biaryl inhibitors of human cathepsin K. J Med Chem (2003) 0.86
Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms. Biochem J (2004) 0.86
In vivo inhibition of serine protease processing requires a high fractional inhibition of cathepsin C. Mol Pharmacol (2008) 0.86
Double-label expression studies of prostacyclin synthase, thromboxane synthase and COX isoforms in normal aortic endothelium. Biochim Biophys Acta (2006) 0.86
Automethylation of protein arginine methyltransferase 6 (PRMT6) regulates its stability and its anti-HIV-1 activity. Retrovirology (2013) 0.85